Brief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
22/09/2026 12:01
BRIEF-Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia Sept 22 (Reuters) - Lexeo Therapeutics, Inc. LXEO.O:
LEXEO THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE MANTLE THERAPEUTICS AND ANNOUNCES MULTIPLE NEW STRATEGIC COLLABORATIONS TO EXPAND LEADERSHIP IN FRIEDREICH ATAXIA
LEXEO THERAPEUTICS, - TO PAY $8.30 MILLION UPFRONT TO MANTLE SHAREHOLDERS
LEXEO THERAPEUTICS, - DEAL INCLUDES UP TO $13 MILLION IN MILESTONE PAYMENTS, TOTAL POTENTIAL $21.30 MILLION
LEXEO THERAPEUTICS, - MAINTAINS CASH RUNWAY GUIDANCE INTO 2028
Source text: ID:nGNX1WWbbB
Further company coverage: LXEO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexeo Therapeutics
See all newsBrief: Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
Brief: Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Lexeo rises as co sets late-stage trial plan for gene therapy in rare heart disease